Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics
NTLA Price/Volume Stats
| Current price | $21.03 | 52-week high | $47.48 |
| Prev. close | $21.32 | 52-week low | $21.02 |
| Day low | $21.02 | Volume | 540,143 |
| Day high | $21.56 | Avg. volume | 1,505,106 |
| 50-day MA | $27.21 | Dividend yield | N/A |
| 200-day MA | $31.15 | Market Cap | 2.03B |
NTLA Stock Price Chart Interactive Chart >
Intellia Therapeutics, Inc. (NTLA) Company Bio
Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Latest NTLA News From Around the Web
Below are the latest news stories about INTELLIA THERAPEUTICS INC that investors may wish to consider to help them evaluate NTLA as an investment opportunity.
13 Most Promising Future Stocks To Buy According To Hedge FundsIn this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. Investing, for the most part, is all […] |
5 Beaten-Down Stocks That Could Soar in 2024These players may offer your portfolio a lift as early as next year. But most importantly, they could excel over time. |
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeuticsbluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog. |
3 Gene-Editing Stocks With the Potential to Mint MillionairesGene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. |
3 Biotechs With Promising Gene Therapies in the SpotlightThe recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline. |
NTLA Price Returns
| 1-mo | -24.30% |
| 3-mo | -17.69% |
| 6-mo | -21.06% |
| 1-year | -41.19% |
| 3-year | -68.80% |
| 5-year | 30.22% |
| YTD | -31.03% |
| 2023 | -12.61% |
| 2022 | -70.49% |
| 2021 | 117.35% |
| 2020 | 270.82% |
| 2019 | 7.47% |
Continue Researching NTLA
Want to see what other sources are saying about Intellia Therapeutics Inc's financials and stock price? Try the links below:Intellia Therapeutics Inc (NTLA) Stock Price | Nasdaq
Intellia Therapeutics Inc (NTLA) Stock Quote, History and News - Yahoo Finance
Intellia Therapeutics Inc (NTLA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...